Twilight Litaka Pharma Ltd
Twilight Litaka Pharma Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceuticals business
- Market Cap ₹ Cr.
- Current Price ₹ 2.88
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -53.4
- Dividend Yield 0.00 %
- ROCE -5.51 %
- ROE %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
- Company has high debtors of 2,421 days.
- Working capital days have increased from 448 days to 949 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
---|---|---|---|---|---|
492 | 671 | 733 | 338 | 32 | |
425 | 572 | 666 | 384 | 40 | |
Operating Profit | 67 | 98 | 67 | -46 | -9 |
OPM % | 14% | 15% | 9% | -14% | -28% |
3 | 3 | -14 | -117 | -127 | |
Interest | 26 | 32 | 47 | 1 | 0 |
Depreciation | 3 | 4 | 6 | 7 | 5 |
Profit before tax | 41 | 66 | 0 | -171 | -142 |
Tax % | 20% | 22% | 532% | -0% | 0% |
33 | 51 | -1 | -171 | -142 | |
EPS in Rs | -0.38 | -68.84 | -57.16 | ||
Dividend Payout % | 10% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -64% |
TTM: | -91% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 72% |
Stock Price CAGR | |
---|---|
10 Years: | -4% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
---|---|---|---|---|---|
Equity Capital | 11 | 11 | 12 | 12 | 12 |
Reserves | 88 | 140 | 167 | -4 | -145 |
195 | 272 | 317 | 322 | 322 | |
66 | 78 | 71 | 129 | 142 | |
Total Liabilities | 360 | 500 | 568 | 460 | 331 |
67 | 91 | 104 | 97 | 91 | |
CWIP | 10 | 19 | 19 | 11 | 11 |
Investments | 0 | 0 | 0 | 0 | 0 |
283 | 390 | 445 | 352 | 229 | |
Total Assets | 360 | 500 | 568 | 460 | 331 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
---|---|---|---|---|---|
14 | -8 | 4 | -5 | 2 | |
-30 | -26 | -19 | 0 | -0 | |
17 | 30 | 14 | 4 | -1 | |
Net Cash Flow | 2 | -3 | -1 | -1 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
---|---|---|---|---|---|
Debtor Days | 133 | 145 | 163 | 285 | 2,421 |
Inventory Days | 67 | 63 | 52 | 68 | 75 |
Days Payable | 33 | 31 | 23 | 39 | 552 |
Cash Conversion Cycle | 166 | 176 | 193 | 313 | 1,944 |
Working Capital Days | 165 | 161 | 175 | 219 | 949 |
ROCE % | 27% | 14% | -13% | -6% |